AlgaHealth has secured NIS 2.5 million led by Kibbutz Ein Shemer, alongside a €50K grant from Horizon 2020, to advance its microalgae production for fucoxanthin, aiming to capitalize on the growing demand for high-quality natural additives.

Information on the Target

AlgaHealth is dedicated to the development of microalgae as a sustainable source for fucoxanthin, a compound increasingly sought after in various sectors, particularly the food industry. This innovative company addresses the significant market demand for high-quality additives, which serve multiple purposes ranging from weight management supplements to treatments for type-2 diabetes and other health issues associated with metabolic syndrome, such as cardiovascular diseases and cancer. Moreover, fucoxanthin is an essential ingredient in anti-aging skincare products, exemplifying its versatility and demand in the market.

What sets AlgaHealth apart is its proprietary production technique that focuses on cultivating unique inland microalgae strains known for their exceptional fucoxanthin yield, potency, and quality. In addition to fucoxanthin, the company aims to produce polysaccharides as a valuable by-product, thereby diversifying its product offerings. The recently raised investment will be allocated to complete the pilot production site and enhance the development of patents related to production processes and product formulations, along with launching products that meet regulatory approvals.

Industry Overview in the Target’s Specific Country

Israel's biotechnology sector has experienced remarkable growth over the past decade, with an increasing number of companies focusing on sustainable practices and health-oriented innovations. The microalgae industry, as part of the larger biotech